Book SummarySickening, by John Abramson

1-Page Summary1-Page Book Summary of Sickening

Unethical Drug Marketing Tactics Harming Patients

This section of our guide delves into the author's exploration of how major pharmaceutical companies manipulate scientific information, leading to the overselling of drugs with limited or even harmful effects. Through two detailed case studies—[restricted term] and [restricted term]—Abramson unveils a pattern of deception that prioritizes industry profits over patient well-being.

[restricted term] Tragedy: Merck's Risk Concealment & NEJM's Complicity Exposed

This section focuses on the [restricted term] scandal, exposing how Merck knowingly hid the cardiovascular dangers linked to the drug, while NEJM, instead of correcting its misleadingly positive review of [restricted term], continued to profit from reprint sales to Merck.

Merck Emails in 2000 Revealed [restricted term]'s Cardiovascular Risks; Journal Article Misrepresented Findings

Abramson presents evidence that by March 2000, Merck knew of [restricted term]'s cardiovascular dangers, when internal emails from Dr. Edward Scolnick, then-head of Merck Research, acknowledged the "clearly there" risks. Despite this, the VIGOR study, designed to assess the drug's gastrointestinal safety, excluded individuals who would have been using aspirin to avert heart attacks, limiting the chance to detect [restricted term]-induced cardiovascular events. The NEJM paper reporting the VIGOR results failed to mention increased heart attack risk, even though eleven of the thirteen authors had financial ties to Merck. Two authors worked for Merck, got Dr. Scolnick's email, and knew about the risks.

Practical Tips

• Practice ethical consumerism by supporting companies with transparent practices. Start by researching the companies behind the products you buy most frequently. Look for evidence of their commitment to transparency, such as clear labeling, open communication about product sourcing, and third-party audits. Choose to purchase from companies that provide this level of openness, which can help you make more informed choices and support ethical business practices.
• Develop a habit of maintaining a 'responsibility log' for your projects or decisions, where you record potential risks and how you're addressing them. This log could be a simple spreadsheet or a dedicated section in your project management tool. When faced with a decision, jot down what could go wrong and note the steps you're taking to mitigate those risks. This practice not only helps you stay organized but also serves as a record of due diligence.
• You can evaluate your personal risk factors for heart disease by creating a health profile with your doctor. Discuss your lifestyle, family history, and any medications you're taking, including aspirin, to get a tailored assessment of your heart health. This personalized profile can help you understand the potential benefits and risks of aspirin therapy for heart attack prevention in your specific case.
• Volunteer for patient advocacy groups that focus on drug safety monitoring. Even without medical expertise, you can contribute by helping to disseminate information on how to report side effects, encouraging participation in post-marketing surveillance studies, or supporting campaigns that raise awareness about the importance of monitoring drug safety. Your involvement could contribute to a larger pool of data that helps detect issues with medications in the broader population.
• Engage in community discussions to gather diverse opinions and insights on topics of interest. Join online forums, social media groups, or local meetups where people discuss the subject matter you're interested in. Actively participate by asking questions about the reliability of different sources and the potential biases they might have. For example, if you're interested in environmental conservation, you could join a local environmental group and start a conversation about how corporate sponsorships might influence certain conservation campaigns or research findings.
• Engage in scenario planning for personal projects or decisions. Take time to consider the best and worst-case scenarios for important choices you face. For instance, if you're considering a major purchase like a car, think through the long-term costs and benefits, potential mechanical issues, and how it fits into your lifestyle to ensure you're aware of all risks involved.

FDA Warns Merck On Misleading Marketing; NEJM Sells Reprints, Enabling Drug Promotion

Abramson reveals a series of events that further highlight Merck's deception and NEJM's complicity. In June 2001, Jennifer Hrachovec, a pharmacist from Seattle, alerted NEJM that its [restricted term] article omitted heart attacks, making the drug appear safer. The New England Journal of Medicine dismissed her concerns. In September 2001, the FDA formally warned Merck, stating the company's marketing downplayed "the potentially serious cardiovascular findings" and was misleading. However, the Food and Drug Administration didn't prevent Merck from purchasing copies of the misleading NEJM article to hand out to doctors, essentially allowing the journal to do its marketing. The NEJM made money by selling reprints, distributing over 929,000 copies—enough for every doctor in the U.S.

Practical Tips

• You can enhance your vigilance on product safety by setting up Google Alerts for news related to medications you or your family members are taking. This way, if there are any reports or studies that raise concerns about a drug's safety, you'll be informed quickly. For example, if you're taking a new prescription drug, create an alert with the drug's name and terms like "side effects" or "study findings" to stay updated on any emerging information.
• Develop a habit of writing letters or emails to editors or organizations when you encounter issues that you believe need attention. This could be in response to something you've read, a product...

Sickening Summary Impact of Commercialization on Integrity in Medical Research

This section explores the author's thesis: that the changing landscape of American society and the prioritization of corporate profits has led to a decline in the integrity and transparency of medical studies, rendering patient care vulnerable to commercial interests.

Drug Companies Influence Clinical Research, Design, Data Analysis, and Publication

This section outlines Abramson's argument that the shift in funding and management of research on treatments from independent universities to commercially driven entities has resulted in a system where the research information provided to physicians is often biased toward maximizing sales rather than optimizing treatments.

Public Funding for Medical Research Declines; Industry Sponsorship Shapes Agenda

Abramson points to a crucial shift starting in the latter part of the 1970s and picking up speed in the 1980s. As government support for medical studies decreased, pharmaceutical companies stepped in to cover the shortfall. Encouraged by legislation like the Bayh-Dole Act, which allowed for the commercialization of federally funded research, academic medical centers increasingly relied on industry funding, leading to a...

Sickening Summary Corporate Effects on Clinical Guidelines and Medical Knowledge

This section addresses Abramson's concern about the commercial bias embedded in the guidelines for clinical practice and insufficient oversight of drug efficacy and pricing in the U.S., resulting in a system geared toward maximizing industry profits at the expense of patient health and well-being.

Industry Funding and Conflicts Influence Professional Societies and Protocol Committees

Abramson highlights the pervasive influence of industry funding on practice guidelines, which are crucial to doctors for evidence-based recommendations. He points out major financial connections between guideline authors and pharmaceutical firms, leading to recommendations that often favor costly, newly developed drugs over effective, cheaper options.

Guidelines Favor Costly New Drugs Over Effective, Cheaper Alternatives Despite Lacking Evidence

Abramson provides several examples of how commercially influenced guidelines result in the promotion of costly medications with limited benefits. He cites the cholesterol guidelines from 2001 and 2004, which recommend statins for healthy women despite the lack of supporting clinical trials, the recommendation of expensive [restricted term]...